PubMed Health⌕ Search

Biomedical subjects

W G Stevenson

Publications and source records attributed to W G Stevenson.

At least 55 records · Page 3Linked to original sources
PubMed1998

Identification and ablation of macroreentrant ventricular tachycardia with the CARTO electroanatomical mapping system.

Monomorphic ventricular tachycardias associated with regions of scar are most commonly due to reentry. Catheter based techniques have recently been described for mapping of reentry circuits. Fluoroscopic methods have obvious limitations when attempting to map large ventricular reentry circuit and localize target-sites of radiofrequency ablation. Three-dimensional right ventricular endocardial mapping was performed in a 38-year-old patient with ventricular tachycardia 28 years after surgical correction of tetralogy of Fallot by using the CARTO electroanatomical system. The map of electrogram voltage showed low amplitude electrograms over the anterior wall of the right ventricle extending into the right ventricular outflow tract, consistent with the location of the ventriculotomy scar. Recording of local activation time was combined with entrainment mapping to define the macroreentrant circuit during ventricular tachycardia. Since the activation propagated through a broad path around the right ventriculotomy scar, ablation was performed by creating a line of block, which was facilitated by tagging of the lesion sites on the endocardial activation map. Large ventricular reentry circuits can be identified and interrupted by creation of a line of block to interrupt a broad path. A practical approach to mapping combining analysis of electrogram voltage, activation sequence, and entrainment is presented.

Adult↗
PubMed1997

Ablation therapy for cardiac arrhythmias.

Ablation has become an important and, in some cases, the first-line therapy for a number of tachyarrhythmias. The feasibility of treating arrhythmias with ablation was initially demonstrated with surgical ablation techniques. Recently, catheter ablation techniques have replaced the surgical approach in nearly all cases. Catheter ablation is highly effective for the Wolff-Parkinson-White syndrome, atrioventricular nodal reentry, and atrial ectopic tachycardia. It is effective for atrial flutter, although approximately one quarter of patients treated with catheter ablation continue to require therapy for concomitant atrial fibrillation. The surgical maze procedure has proved to be feasible for preventing atrial fibrillation. The risks and long-term efficacy of catheter ablation maze procedures for atrial fibrillation need to be defined. The efficacy of ablation for ventricular tachycardia varies with the type of tachycardia. Catheter ablation is very effective for the rare idiopathic ventricular tachycardias that occur in structurally normal hearts and for bundle-branch reentry ventricular tachycardia, which occurs most frequently in patients with dilated cardiomyopathy. When performed at an experienced center, surgical ablation is an excellent option for selected patients with ventricular tachycardia due to prior myocardial infarction who have a discrete aneurysm but otherwise well-preserved ventricular function. Catheter ablation shows promise for this arrhythmia, but it can be offered only to those patients who have relatively slow tachycardias that allow catheter mapping. Substantial advances in mapping and ablation technology will continue to occur, allowing nonpharmacologic control of cardiac arrhythmias to be achieved in an ever greater number of patients.

Arrhythmias, Cardiac↗
PubMed1997

Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital.

BACKGROUND: The risks of antiarrhythmic therapy are increasingly recognized, but the risks associated with the initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation are poorly defined. OBJECTIVE: To determine the incidence, time course, and predictors of adverse cardiac events that require intervention during initiation of antiarrhythmic drug therapy for atrial fibrillation. DESIGN: Retrospective chart review. SETTING: University hospital. PARTICIPANTS: 417 consecutive patients who underwent a total of 597 drug trials during a total of 550 hospitalizations for atrial fibrillation. INTERVENTION: Initiation of therapy with antiarrhythmic drugs: procainamide (189 trials), quinidine (179 trials), disopyramide (20 trials), propafenone (110 trials), flecainide (2 trials), sotalol (72 trials), and amiodarone (25 trials). Electrical conversion was performed during 247 trials. MEASUREMENTS: Incidence of adverse events and daily hazard rate were measured. Logistic regression was done to identify risk factors. RESULTS: During the 597 drug trials, 80 (13.4%) cardiac adverse events occurred in 73 patients. The risk was greatest during the first 24 hours of therapy. Bradyarrhythmias were the most common adverse event, occurring in 47 trials (7.9%); prolongation of the QT interval warranting discontinuation of drug therapy (9 trials; 1.5%) and ventricular arrhythmias (8 trials; 1.3%) were less frequent. In multivariate analysis, previous myocardial infarction was associated with increased risk (odds ratio, 1.90 [95% CI, 1.05 to 3.43]) and the association between older age and increased risk (odds ratio, 1.29 per decade [CI, 0.97 to 1.72]) was of borderline statistical significance. CONCLUSIONS: A significant risk for cardiac adverse events exists during initiation of antiarrhythmic therapy in patients hospitalized for atrial fibrillation. Observation with electrocardiographic monitoring seems advisable for 24 to 48 hours during initiation of antiarrhythmic therapy, particularly for elderly patients and patients who have previously had myocardial infarction.

Adult↗
PubMed1997

Predicting prescribing costs in general practice using practice demography.

Prescription and dispensing costs form a large part (c. 56%) of primary care expenditure in the NHS and concern has been expressed at its ever increasing total. Previous predictive models have either failed to account for a high proportion of costs or else have not been able to explain adequately the role practice list demography plays upon costs. Using prescription data and the practice demography, our model accounts for 91.4% of the variation in primary health care prescribing costs in Northern Ireland thus explaining them to a much greater extent than previous models and, in addition, explains a large part of the variation in total monthly consultations and numbers of prescriptions. In addition to comprehensiveness it has a high degree of parsimony, needing only three independent variables for each practice, namely, the number of children aged 0-4 years, the number of persons aged 60+ years and the number of partners in the practice, all of which are immediately comprehensible by GPs and their negotiators. Thus, it could form a valuable addition to the 'evaluation kit' of prescribing advisers and others concerned with auditing and containing costs. Previous studies have shown the importance of the age-sex structure of practice lists in relation to prescribing costs but none has been able to develop such a powerful, simple and comprehensible predictive model.

Journal Article↗
PubMed1997

Exploring postinfarction reentrant ventricular tachycardia with entrainment mapping.

Ventricular tachycardia late after myocardial infarction is usually due to reentry in the infarct region. These reentry circuits can be large, complex and difficult to define, impeding study in the electrophysiology laboratory and making catheter ablation difficult. Pacing through the electrodes of the mapping catheter provides a new approach to mapping. When pacing stimuli capture the effects on the tachycardia depend on the location of the pacing site relative to the reentry circuit. The effects observed allow identification of various portions of the reentry circuit, without the need for locating the entire circuit. Isthmuses where relatively small lesions produced by radiofrequency catheter ablation can interrupt reentry can often be identified. A classification that divides reentry circuits into one or more functional components helps to conceptualize the reentry circuit and predicts the likelihood that heating with radiofrequency current will terminate tachycardia. These methods are helping to define human reentry circuits.

Cardiac Pacing, Artificial↗
PubMed1997

Catheter ablation of ventricular tachycardia after myocardial infarction: relation of endocardial sinus rhythm late potentials to the reentry circuit.

OBJECTIVES: We sought to determine whether endocardial late potentials during sinus rhythm are associated with reentry circuit sites during ventricular tachycardia (VT). BACKGROUND: During sinus rhythm, slow conduction through an old infarct region may depolarize tissue after the end of the QRS complex. Such slow conduction regions can cause reentry. METHODS: Endocardial catheter mapping and radiofrequency ablation were performed in 24 patients with VT late after myocardial infarction. We selected for analysis a total of 103 sites where the electrogram was recorded during sinus rhythm and, without moving the catheter, VT was initiated and radiofrequency current applied in an attempt to terminate VT. RESULTS: Late potentials were present at 34 sites (33%). During pace mapping, the stimulus-QRS complex was longer at late potential sites, consistent with slow conduction, than at sites without late potentials (p < 0.0001). Late potentials were present at 15 (71%) of 21 sites classified as central or proximal in the reentry circuit based on entrainment, but also occurred frequently at bystander sites (13 [33%] of 39) and were often absent at the reentry circuit exit (3 [23%] of 13). Late potentials were present at 20 (54%) of 37 sites where ablation terminated VT, compared with 14 (21%) of 66 sites where ablation did not terminate VT (p = 0.004). Ablation decreased the amplitude of the late potentials present at sites where ablation terminated VT. CONCLUSIONS: Although sites with sinus rhythm late potentials often participate in VT reentry circuits, many reentry circuit sites do not have late potentials. Late potentials can also arise from bystander regions. Late potentials may help identify abnormal regions in sinus rhythm but cannot replace mapping during induced VT to guide ablation.

Action Potentials↗
PubMed1997

Pharmacologic and nonpharmacologic treatment of ventricular arrhythmias in heart failure.

Ventricular arrhythmias are common in patients with heart failure. The risk and benefits of antiarrhythmic therapies continue to be defined. Class I antiarrhythmic drugs should be avoided due to proarrhythmic and negative inotropic effects that may be responsible for increased mortality in some trials. For patients resuscitated from sustained ventricular tachycardia or ventricular fibrillation, amiodarone or an implantable cardioverter-defibrillator should be considered. Implantable cardioverter-defibrillators markedly reduce sudden death in ventricular tachycardia and ventricular fibrillation survivors, but in advanced heart failure, this may not markedly extend survival. Catheter or surgical ablation can be considered for selected patients with bundle branch reentry ventricular tachycardia or difficult to control monomorphic ventricular tachycardia. For patients who have not had sustained ventricular tachycardia or ventricular fibrillation antiarrhythmic therapy should generally be avoided, but may benefit some high risk patients. Amiodarone may be beneficial in patients with advanced heart failure and rapid resting heart rates. Implantable cardioverter-defibrillators may improve survival in selected patients with depressed ventricular function after myocardial infarction, who also have nonsustained and inducible ventricular tachycardia.

Amiodarone↗
PubMed1997

Preferential locations for critical reentry circuit sites causing ventricular tachycardia after inferior wall myocardial infarction.

INTRODUCTION: For relatively slow monomorphic ventricular tachycardia (VT) after myocardial infarction, entrainment can be used to identify reentry circuit "isthmus sites" (exit sites and sites proximal to the exit) where radiofrequency (RF) catheter ablation has the greatest likelihood of interrupting reentry. Similarities in coronary and ventricular anatomy may cause such sites to form in preferential locations. The objective of this study is to determine if there are preferential locations for reentry circuit isthmus regions in chronic inferior wall infarctions causing VT. METHODS AND RESULTS: Catheter mapping and RF catheter ablation was performed in 21 patients with an old inferior wall myocardial infarction and VT. The inferior wall was divided into 9 anatomic regions: 3 apical, 3 mid, and 3 basal segments. Of 46 different VTs, an endocardial isthmus site was identified in one or more zones in 28 (61%), with 10 VTs having isthmus sites in two or more adjacent regions. Isthmus zones were found in a basal region of the left ventricle in 24 (86%) of 28 VTs, in a mid segment in 9 (32%) VTs, and in an apical segment in 1 (4%) (P = 0.002). Of 30 RF current applications that terminated VT, 21 (70%) were at basal isthmus sites. CONCLUSION: The high prevalence of endocardial isthmus zones near the base of the left ventricle suggests that the mitral annulus often plays a role in defining the margins of reentry circuits that cause relatively slow VTs after inferior wall myocardial infarction.

Aged↗
PubMed1997

Effect of recording site on postpacing interval measurement during catheter mapping and entrainment of postinfarction ventricular tachycardia.

INTRODUCTION: During entrainment of reentrant ventricular tachycardia (VT), the difference between the postpacing interval (PPI) and the VT cycle length (VTCL) measured at the pacing site is an indication of the conduction time from the pacing site to the reentry circuit. The difference is usually < or = 30 msec at successful ablation sites. However, electrical noise during pacing sometimes obscures the electrograms recorded directly from the pacing site. The objective of this study is to determine if the PPI-VTCL difference measured at the mapping catheter electrodes proximal to the stimulating electrode accurately predicts the PPI-VTCL difference at the stimulating electrode. METHODS AND RESULTS: Endocardial catheter mapping was performed in 26 patients with infarct-related VT. At 191 sites during 56 VTs, unipolar pacing from the distal electrode entrained VT and electrograms recorded from the mapping catheter were discernable following pacing in both the bipolar recordings from the distal electrode pair (BI 1-2) and the electrode pair 6 mm proximal to the distal electrode (BI 3-4). The PPI-VTCL difference at BI 1-2 correlated well with that measured at BI 3-4 (r = 0.88, P = 0.001). A PPI-VTCL difference at BI 3-4 < or = 30 msec predicted a PPI-VTCL difference at BI 1-2 < or = 30 msec with a sensitivity of 95%, specificity of 87 %, and predictive accuracy of 91%. CONCLUSIONS: Measurement of the PPI from electrodes proximal to the stimulating electrode is a reasonable alternative when the PPI cannot be assessed from the pacing electrode.

Aged↗
PubMed1997

Ablation of ventricular tachycardia due to a postinfarct ventricular septal defect: identification and transection of a broad reentry loop.

INTRODUCTION: Ventricular tachycardia (VT) after postinfarct ventricular septal defect (VSD) repair has not been well characterized. METHODS AND RESULTS: A 55-year-old man developed refractory VT after inferior wall infarction and VSD repair. Entrainment demonstrated a broad reentry circuit path (outer loop) between the tricuspid annulus and VSD patch. A series of radiofrequency (RF) lesions transected this path, abolishing VT and producing conduction block between the inferior and superior aspects of the basal right ventricular septum. CONCLUSION: Some VTs have broad reentry loops requiring ablation by a series of RF lesions across the path to create a line of block. This approach is analogous to that for atrial flutter.

Catheter Ablation↗
PubMed1997

Arrhythmias and sudden death in heart failure.

Survival of patients with heart failure has improved over the past decade due to advances in medical therapy. Sudden death continues to cause 20 to 50% of deaths. Ventricular arrhythmias are common in patients with heart failure. Ventricular hypertrophy, scars from prior myocardial infarction, sympathetic activation, and electrolyte abnormalities contribute. Some sudden deaths are due to bradyarrhythmias and electromechanical dissociation rather than ventricular arrhythmias. The risks and benefits of antiarrhythmic therapies continue to be defined. Class I antiarrhythmic drugs should be avoided due to proarrhythmic and negative inotropic effects that may increase mortality. For patients resuscitated from sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) amiodarone or an implantable cardioverter defibrillator (ICD) should be considered. ICDs markedly reduce sudden death in VT/VF survivors, but in advanced heart failure, this may not markedly extend survival. Catheter or surgical ablation can be considered for selected patients with bundle branch reentry VT or difficult to control monomorphic VT. For patients who have not had sustained VT/VF antiarrhythmic therapy should generally be avoided, but may benefit some high risk patients. Amiodarone may be beneficial in patients with advanced heart failure and rapid resting heart rates. ICDs may improve survival in selected survivors of myocardial infarction who have inducible VT.

Adrenergic beta-Antagonists↗
PubMed1997

Six-minute walk test and heart rate variability: lack of association in advanced stages of heart failure.

BACKGROUND: The 6-minute walk and heart rate variability have been used to assess mortality risk in patients with heart failure, but their relationship to each other and their usefulness for predicting mortality at 1 year are unknown. OBJECTIVE: To assess the relationships between the 6-minute walk test, heart rate variability, and 1-year mortality. METHOD: A sample of 113 patients in advanced stages of heart failure (New York Heart Association Functional Class III-IV, left ventricular ejection < 0.25) were studied. All 6-minute walks took place in an enclosed, level, measured corridor and were supervised by the same nurse. Heart rate variability was measured by using (1) a standard-deviation method and (2) Poincaré plots. Data on RR intervals obtained by using 24-hour Holter monitoring were analyzed. Survival was determined at 1 year after the Holter recording. RESULTS: The results showed no significant associations between the results of the 6-minute walk and the two measures of heart rate variability. The results of the walk were related to 1-year mortality but not to the risk of sudden death. Both measures of heart rate variability had significant associations with 1-year mortality and with sudden death. However, only heart rate variability measured by using Poincaré plots was a predictor of total mortality and risk of sudden death, independent of left ventricular ejection fraction, serum levels of sodium, results of the 6-minute walk test, and the standard-deviation measure of heart rate variability. CONCLUSIONS: Results of the 6-minute walk have poor association with mortality and the two measures of heart rate variability in patients with advanced-stage heart failure and a low ejection fraction. Further studies are needed to determine the optimal clinical usefulness of the 6-minute walk and heart rate variability in patients with advanced-stage heart failure.

Death, Sudden↗
PubMed1997

Pace-mapping conduction delay at reentry circuit sites of ventricular tachycardia after myocardial infarction.

This study was carried out to determine the relationship of conduction delay during pace-mapping, as indicated by the stimulus to QRS interval to different reentry circuit sites and bystanders, as identified by entrainment criteria, in patients with ventricular tachycardia late after myocardial infarction. Catheter mapping and ablation were performed in 40 patients with ventricular tachycardia after myocardial infarction. Data were retrospectively analyzed from 122 endocardial sites which met the following the criteria: a 12-lead electrocardiogram was recorded during pace-mapping, ventricular tachycardia was then induced and entrained by pacing to classify the type of the site relative to the reentry circuit exit. By entrainment criteria 77 sites were in the reentry circuit (28 exit sites, 49 other circuit sites) and 45 sites were bystanders not in the reentry circuit. The average stimulus conduction delay at central/proximal sites was 103 +/- 43 ms, which was significantly longer than at exit (57 +/- 31 ms), outer loop sites (57 +/- 32 ms), and bystander sites (57 +/- 37 ms); P < 0.05. Pace-mapping revealed evidence of greater conduction delay at sites proximal to the reentry circuit exit, consistent with slow conduction between these regions and the border of the infarct. Exit sites and outer loop sites were more likely to be located along the border of the infarct, with less conduction delay evident during pace-mapping.

Cardiac Pacing, Artificial↗
PubMed1996

Improving survival for patients with atrial fibrillation and advanced heart failure.

OBJECTIVES: We attempted to determine whether changes in heart failure therapy since 1989 have altered the prognostic significance of atrial fibrillation. BACKGROUND: Atrial fibrillation occurs in 15% to 30% of patients with heart failure. Despite the recognized potential for adverse effects, the impact of atrial fibrillation on prognosis is controversial. METHODS: Two-year survival for 750 consecutive patients discharged from a single hospital after evaluation for heart transplantation from 1985 to 1989 (Group I, n = 359) and from 1990 to April 1993 (Group II, n = 391) was analyzed in relation to atrial fibrillation. In Group I, class I antiarrhythmic drugs and hydralazine vasodilator therapy were routinely allowed. In Group II, amiodarone and angiotensin-converting enzyme inhibitors were first-line antiarrhythmic and vasodilating drugs. RESULTS: A history of atrial fibrillation was present in 20% of patients in Group I and 24% of those in Group II. Patients with atrial fibrillation in the two groups had similar clinical and hemodynamic profiles. Among patients with atrial fibrillation, those in Group II had a markedly better 2-year survival (0.66 vs. 0.39, p = 0.001) and sudden death-free survival (0.84 vs. 0.70, p = 0.01) than those in Group I. In each time period, survival was worse for patients with than without atrial fibrillation in Group I (0.39 vs. 0.55, p = 0.002) but not in Group II (0.66 vs. 0.75, p = 0.09). CONCLUSIONS: The prognosis of patients with advanced heart failure and atrial fibrillation is improving. These findings support the practice of avoiding class I antiarrhythmic drugs in this group and may reflect recent beneficial changes in heart failure therapy.

Adult↗